KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

April 22, 2019 Off By BusinessWire

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24KALV&src=ctag” target=”_blank”gt;$KALVlt;/agt;–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, announced today
that Daniel Soland has been appointed to its Board of Directors
effective immediately. Mr. Soland most recently served as the Chief
Executive Officer of uniQure N.V. and Senior Vice President and Chief
Operating Officer of ViroPharma.

“Dan is an experienced leader in the life sciences industry, with
particular expertise in commercial and marketing operations in
hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive
Officer of KalVista. “We are pleased to have Dan join as an independent
director who will further strengthen our Board. We look forward to his
insights as we continue to advance our oral plasma kallikrein inhibitors
for potential treatment of HAE and begin to develop our commercial and
market strategy.”

“I am excited to join KalVista’s Board and collaborate with them and the
leadership team to deliver potential new treatments for diseases with
unmet need,” said Mr. Soland. “I look forward to working with KalVista
as they advance towards becoming a commercial stage company.”

In addition to his most recent positions, Mr. Soland has an extensive
background in the pharmaceutical industry. He currently serves on the
Boards of Directors of Acadia Pharmaceuticals and DBV Technologies. Mr.
Soland served as President of Chiron Vaccines until the acquisition of
Chiron by Novartis. Prior to that, he was President and Chief Executive
Officer of Epigenesis Pharmaceuticals and earlier was Vice President and
Director, Worldwide Marketing Operations for GlaxoSmithKline
Biologicals. Earlier in his career, Mr. Soland held positions of
increasing responsibility in sales and product management at
Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy
from the University of Iowa.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on
the discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which, in
excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of novel,
small molecule plasma kallikrein inhibitors initially targeting
hereditary angioedema (HAE) and diabetic macular edema (DME). The
Company has created a structurally diverse portfolio of oral plasma
kallikrein inhibitors and is advancing multiple drug candidates for HAE
as well as DME. The Company has selected KVD900 as its program to be
advanced as an on-demand therapy for HAE attacks and commenced a Phase 2
proof-of-concept study in HAE patients in late 2018. In DME, KalVista’s
most advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that
is anticipated to complete in the second half of 2019.

For more information, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains “forward-looking” statements within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “anticipate,” “intend,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references to
future periods. These statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
what we expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical trial
timing and results. Further information on potential risk factors that
could affect our business and its financial results are detailed in the
annual report on Form 10-K filed on July 30, 2018 and other reports as
filed from time to time with the Securities and Exchange Commission. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.